In pregnant women with MS given ocrelizumab, treatment did not result in infant B-cell depletion after birth, and the drug was virtually undetectable in the bloodstream of mother and child, according to a poster from ECTRIMS 2024.
Treatment with diroximel fumarate was linked to lower rates of severe infection compared with anti-CD20 monoclonal antibodies for adults of all ages with MS, according to a poster presented at ECTRIMS.
Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.
Among individuals who were prescribed approved biologics for neuromyelitis optica spectrum disorder, those on inebilizumab had significantly higher medication adherence, according to a study presented at ECTRIMS 2024.
